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During Transcatheter Aortic Valve
Implantation for Improved Valve SizingPolykarpos C. Patsalis, MD,* Fadi Al-Rashid, MD,* Till Neumann, MD,* Björn Plicht, MD,*
Heike A. Hildebrandt, MD,* Daniel Wendt, MD,y Matthias Thielmann, MD,y
Heinz G. Jakob, MD,y Gerd Heusch, MD,z Raimund Erbel, MD,* Philipp Kahlert, MD*
Essen, GermanyObjectives This study sought to evaluate whether supra-aortic angiography during preparatory
balloon aortic valvuloplasty (BAV) improves valve sizing.
Background Current recommendations for valve size selection are based on annular measurements
by transesophageal echocardiography and computed tomography, but paravalvular aortic
regurgitation (PAR) is a frequent problem.
Methods Data of 270 consecutive patients with either conventional sizing (group 1, n ¼ 167) or
balloon aortic valvuloplasty–based sizing (group 2, n ¼ 103) were compared. PAR was graded
angiographically and quantitatively using several hemodynamic indices.
Results PAR was observed in 113 patients of group 1 and 41 patients of group 2 (67.7% vs. 39.8%,
p < 0.001). More than mild PAR was found in 24 (14.4%) patients of group 1 and 8 (7.8%) patients of
group 2. According to pre-interventional imaging, 40 (39%) patients had a borderline annulus size,
raising uncertainty regarding valve size selection. Balloon sizing resulted in selection of the bigger
prosthesis in 30 (29%) and the smaller prosthesis in the remaining patients, and only 1 of these 40
patients had more than mild PAR. As predicted by the hemodynamic indices of PAR, mortality at 30
days and 1 year was less in group 2 than in group 1 (5.8% vs. 9%, p ¼ 0.2 and 10.6% vs. 20%, p ¼ 0.01).
Conclusions Preparatory balloon aortic valvuloplasty during transcatheter aortic valve implantation
improves valve size selection, reduces the associated PAR, and increases survival in borderline
cases. (J Am Coll Cardiol Intv 2013;6:965–71) ª 2013 by the American College of Cardiology
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966Paravalvular aortic regurgitation (PAR) after transcatheter
aortic valve implantation (TAVI) is associated with increased
in-hospital mortality and unfavorable long-term outcome
(1). Reduction of PAR by appropriate valve size selection is
key. Current recommendations for valve size selection are
based on transesophageal echocardiography, but multislice
computed tomography (MSCT) is increasingly used (2). The
choice of correct prosthesis size based on pre-interventionalSee page 972
Abbreviations
and Acronyms
AR index = aortic
regurgitation index
BAV = balloon aortic
valvuloplasty
DAP = diastolic aortic
pressure
DPTI = diastolic pressure
time integral
DPTI:SPTI = ratio of diastolic
over systolic pressure time
integral
DPDAP–LVEDP = pressure
gradient between DAP and
LVEDP
LV = left ventricular
LVEDP = left ventricular end-
diastolic pressure
MCV = Medtronic CoreValve
MSCT = multislice computed
tomography
PAR = paravalvular aortic
regurgitation
SPTI = systolic pressure time
integral
TAVI = transcatheter aortic
valve implantation
TEE = transesophageal
echocardiographyimaging of annular size can be
difﬁcult, and relevant PAR with
negative impact on survival still
results in up to 20% of cases
(1–15). TAVI generally requires
preparatory balloon aortic valvu-
loplasty (BAV) to facilitate the
prosthesis implantation and ex-
pansion. Accurate annular sizing
remains challenging and is
a prerequisite for reduction of
PAR and associated mortality.
The purpose of the present
study, therefore, was to evaluate
whether supra-aortic angiog-
raphy during BAV improves
valve size selection and reduces
PAR especially in cases with
borderline annulus size.Methods
Patient population. Data from
270 consecutive high-risk patients
with symptomatic aortic valve
stenosis who underwent trans-
femoral or transsubclavian TAVI
using the Medtronic CoreValve
(MCV) (Medtronic Inc., Min-
neapolis, Minneapolis; n ¼ 104
[38.5%]) or the Edwards Sapien(Edwards Lifesciences Inc., Irvine, California; n ¼ 166
[61.5%]) bioprosthesis were analyzed: 167 patients under-
went conventional sizing by echocardiography (conventional
sizing) and were compared with 103 subsequent patients, in
whom BAV was additionally used for valve size selection
(balloon sizing). The decision for TAVI was made by an
interdisciplinary heart team (10,12,16–19). TAVI proce-
dures were performed according to standard techniques
(16,18,19).
Valve size selection. There is an overlap between 2
different prosthesis sizes for both the MCV and theEdwards Sapien bioprostheses where valve size selection is
left to the physician’s choice. For conventional sizing
(group 1), the choice of the prosthetic size was based
on pre-interventional transesophageal echocardiography
(TEE) by an experienced investigator (2–10). For balloon
sizing (group 2), patients underwent preparatory BAV
(Z-MED balloon, NuMED, Inc., Hopkinton, New York or
Edwards balloon) during TAVI. Supra-aortic angiography
during BAV was used to measure the size of the aortic
annulus. At the time of full balloon inﬂation, supra-aortic
angiography was performed perpendicular to the native
valve plane in a slight cranial/left anterior oblique projec-
tion over a 6-F pigtail catheter (Cordis Corporation,
East Bridgewater, New Jersey) placed in the noncoronary
cusp. Contrast regurgitation into the left ventricle after
injection of 20 ml of contrast at a ﬂow rate of 10 ml/s
served to indicate annulus size underestimation by TEE
and resulted in the selection of a bigger prosthesis (Fig. 1,
Online Video 1). For TAVI using the Edwards Sapien
bioprosthesis, balloon sizing was performed with a 23-mm
Edwards balloon for selection between the 23- and 26-mm
valve and with a 25-mm Z-MED balloon for selection
between the 26- and 29-mm valve. For TAVI using the
MCV, balloon sizing was performed with a 23-mm
Z-MED balloon for selection between the 26- and 29-mm
valve and with a 25-mm Z-MED balloon for selection
between the 29- and 31-mm valve. In order to achieve
a 23-mm diameter using the 23-mm Edwards balloon or
the 23-mm Z-MED balloon, inﬂation with 21 ml of
saline/contrast mixture was necessary. In order to achieve
a 25-mm diameter using the 25-mm Z-MED balloon inﬂa-
tion with 22 ml was necessary. A diameter of 26 mm was
achieved by inﬂating the 25-mmZ-MED balloon with 23ml
of saline/contrast mixture. Of note, a 26-mm balloon was not
available in our catheterization laboratory at that time. The
volume needed to achieve a certain diameter was calibrated in
vitro using a saline/contrast medium mix. To evaluate the
congruence between the aortic annulus and the device, we also
calculated the “cover index” as a ratio of: 100  ([prosthesis
diameter TEE annulus diameter]/prosthesis diameter) (7).
PAR severity. The severity of residual PAR was graded
qualitatively by the amount of regurgitating contrast
medium during supra-aortic angiography after ﬁnal device
deployment and catheter removal using the Sellers criteria
(12,14,20): absent 0/4; mild 1/4; moderate 2/4; moderate-
to-severe 3/4; and severe 4/4. Simultaneous left ventricular
(LV) and aortic pressures were recorded at 50 mm/s and
averaged over 3 representative cardiac cycles after the
procedure. The aortic regurgitation index (AR index) as the
ratio of the gradient between diastolic aortic pressure and
left ventricular end-diastolic pressure (LVEDP) to systolic
blood pressure  100 (11), the pressure gradient between
diastolic aortic pressure (DAP) and left ventricular end-
diastolic pressure (DPDAP–LVEDP) (14), and the myocardial
Figure 1. Supra-Aortic Angiography During Preparatory BAV for Valve Size Selection
(A) After balloon inﬂation, supra-aortic angiography was performed with a 23-mm balloon. Contrast regurgitation into the left ventricle was an indicator of annulus size
underestimation by transesophageal echocardiography and resulted in the selection of a bigger prosthesis. (B) Absence of contrast regurgitation into the left ventricle
during balloon sizing with a 23-mm balloon conﬁrmed annular sizing based on pre-interventional transesophageal echocardiography and resulted in the selection of
the smaller prosthesis. See Online Video 1 for an accompanying video. BAV ¼ balloon aortic valvuloplasty.
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967supply-demand ratio (DPTI:SPTI) (15) from planimetric
integration of the diastolic pressure time integral (DPTI) and
systolic pressure time integral (SPTI) were calculated. An AR
index<25, aDPDAP–LVEDP18mmHg, and a DPTI:SPTI
0.7 have been previously proposed as cutoff values for
increased mortality associated with PAR after TAVI.
Endpoint. The primary endpoint was mortality over the
duration of the study according to Valve Academic Research
Consortium II deﬁnitions (19). All patients were followed
for at least 1 year.
Post-interventional protocol. After TAVI, patients were
transferred for 24 h to an intensive care unit for post-
interventional monitoring. Besides the clinical examination,
electrocardiogram, body temperature, and chest x-ray, all
blood parameters, which had already been determined at the
initial examination, were determined again. Follow-up
examinations were performed 3 months and 1 year after
discharge.
Statistical analysis. Categorical data are presented as fre-
quencies and percentages; continuous variables are pre-
sented as mean  SD. The normal distribution of the
variables was tested by the Shapiro-Wilk test (p-Wert
0.1). Comparisons were made with 2-sided chi-square
tests or 2-sided Fisher exact tests for categorical variables
and 1-way analysis of variance for continuous variables,
using Bonferroni correction for multiple testing. Analysis of
variance and the Student t test were used to compare
normally distributed variables (age, aortic annulus, weight,
height) and the Mann-Whitney U test was used comparethe other non-normally distributed variables between the 2
groups. A p value of <0.05 was considered signiﬁcant.
Survival analyses for conventional and balloon sizing were
performed by the Kaplan-Meier method, with patients
censored as of the last date known alive. All statistical
analyses were performed using SPSS (version 17.0, SPSS,
Chicago, Illinois).
Results
Baseline and procedural characteristics. Our study cohort
represents a typical TAVI patient population at high risk for
open-heart surgery (logistic EuroSCORE [European System
for Cardiac Operative Risk Evaluation]: 21.0  12.8%, STS
[Society of Thoracic Surgeons] score: 7.7  6.7%) with
symptomatic aortic stenosis (aortic valve area: 0.63 
0.2 cm2, transvalvular gradient: 55.7  9.6 mm Hg). There
were no signiﬁcant differences in baseline and procedural
characteristics between the retrospective conventional-sizing
group and the balloon-sizing group (Tables 1 and 2).
BAV for valve size selection. For 63 (61%) patients of group
2 who had a distinct annulus size, balloon sizing was used to
conﬁrm annular sizing based on the pre-interventional
TEE. In all 63 patients, absence of contrast regurgitation
into the LV after balloon inﬂation conﬁrmed annulus sizing
by TEE and resulted in the implantation of the expected
valve size (Fig. 2).
In cases of borderline annulus size, balloon sizing was
used for valve size selection. According to pre-interventional
Table 1. Baseline Characteristics
Overall
(n ¼ 270)
Conventional Sizing
(n ¼ 167)
Balloon Sizing
(n ¼ 103) p Value
Age, yrs 80.9  6.2 80.7  6.6 81.5  5.3 0.2
Male 110 (40.7) 70 (41.9) 40 (38.8) 0.7
Weight, kg 75.5  13.2 75.2  14.2 76.3  14.1 0.5
Height, cm 166.4  7.4 166.2  8.3 167.1  6.4 0.31
Logistic EuroSCORE, % 17.9 (16.0, 27.1) 18.3 (16.1, 26.7) 16.8 (15.7, 27.7) 0.2
STS score, % 7.3 (6.7, 9.1) 7.2 (6.8, 8.7) 7.5 (7.1, 9.3) 0.6
Aortic valve area, cm2 0.61 (0.5, 0.7) 0.60 (0.5, 0.7) 0.65 (0.5, 0.8) 0.15
Mean transvalvular PG, mm Hg 54.7 (46.0, 61.0) 55.0 (48.0, 63.0) 54.0 (47.0, 60.0) 0.2
LVEF, % 52 (42.0, 56.0) 51 (40.0, 55.0) 53 (43.0, 56.0) 0.36
Aortic annulus diameter, mm 22.9  1.9 22.8  1.4 23.1  1.4 0.08
CAD 174 (64.4) 105 (62.9) 69 (66.9) 0.5
Prior MI 10 (3.7) 4 (2.4) 6 (5.8) 0.2
Prior PCI 107 (39.6) 62 (37.1) 45 (43.7) 0.4
Prior heart surgery 47 (17.4) 28 (16.8) 19 (18.4) 0.75
PVD 38 (14.0) 25 (15.0) 13 (12.6) 0.7
Values are mean  SD, n (%), or median (interquartile range).
CAD¼ coronary artery disease; EuroSCORE¼ European System for Cardiac Operative Risk Evaluation; LVEF¼ left ventricular ejection fraction; MI¼myocardial
infarction; PCI ¼ percutaneous coronary intervention; PG ¼ pressure gradient; PVD ¼ peripheral vascular disease; STS ¼ Society of Thoracic Surgeons.
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968imaging by TEE, 40 (39%) patients had a borderline
annulus size. Balloon sizing performed in these cases
revealed an underestimation of annulus size in 30 patients
(29%), so that on-table the bigger prosthesis was selected,
whereas the smaller prosthesis was chosen in the remaining
patients, resulting in only 1 of these 40 patients with at least
moderate PAR (Fig. 2). Of note, there were no complications
associated with angiography during BAV. Speciﬁcally, there
were no annulus ruptures associated with balloon sizing.
PAR after TAVI. The angiographic assessment of post-
procedural PAR revealed a lower frequency of PAR in the
balloon sizing than in the retrospective conventional sizing
group (Table 3A). At least mild PAR was observed in 113
patients of the retrospective conventional-sizing group and
41 patients of the balloon-sizing group. Severe PAR did not
occur in any of our study patients (67.7% vs. 39.8%, p <
0.001).Table 2. Procedural Characteristics
Overall
(n ¼ 270)
Transfemoral 260 (96.3)
Transsubclavian 10 (3.7)
CoreValve 104 (38.5)
Edwards 166 (61.5)
Procedural duration, min 71.1 (53.0–101.0)
Fluoroscopy time, min 13.5 (10.6–17.9)
Contrast amount, ml 175 (134.0–207.0)
Post-procedural transvalvular mean PG, mm Hg 9.3 (7.0–14.0)
Values are n (%) or median (interquartile range).
PG ¼ pressure gradient.An AR index <25, a pressure difference 18 mm Hg,
and a DPTI:SPTI 0.7 were observed less often in patients
who underwent balloon sizing than in those who underwent
conventional sizing (Table 3B).
There was a tendency toward a lower cover index in the
retrospective conventional-sizing group compared with the
balloon-sizing cohort but without signiﬁcance (6.4  5% vs.
6.8  6%, respectively, p ¼ 0.6). Correcting maneuvers for
PAR treatment in the retrospective conventional-sizing
group have been described before (14). Twenty-three
patients underwent post-dilation with an improvement in
PAR grade to <2/4 in 13 (54%) of them. One patient with
severe PAR due to low implantation of a MCV underwent
post-deployment repositioning by snaring, which resulted in
PAR improvement to 1/4. In the balloon-sizing cohort, 10
patients underwent post-dilation with an improvement in
PAR grade to <2/4 in 2 (20%) of them. The reduced rate ofConventional Sizing
(n ¼ 167)
Balloon Sizing
(n ¼ 103) p Value
158 (94.6) 102 (99) 0.095
9 (5.4) 1 (1.0) 0.095
88 (52.7) 16 (15.5) <0.001
79 (47.3) 87 (84.5) <0.001
72.0 (55.0–105.0) 69.2 (50.0–95.0) 0.16
13.1 (10.3–17.5) 14.0 (11.1–18.5) 0.1
173.5 (130.0–205.0) 179.6 (137.0–210.0) 0.4
9.0 (6.0–13.0) 9.7 (7.3–13.9) 0.2
Figure 2. Balloon Sizing
According to pre-interventional transesophageal echocardiography, 40
patients had a borderline annulus size. When balloon sizing was performed, it
revealed an underestimation of annulus size in 30 patients (29%), so that
on-table, a bigger prosthesis was selected.
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969post-dilation due to the reduced incidence of PAR in the
balloon-sizing group did not signiﬁcantly affect stroke rate.
PAR and associated mortality in relation to the sizing
method. Mortality at 30 days and 1 year was less in patients
who underwent additional balloon sizing in comparison to
thosewhounderwent conventional sizing (5.8%vs. 9%, p¼ 0.2,
and 10.6% vs. 20%, p ¼ 0.01) (Fig. 3).Discussion
The present study is the ﬁrst to demonstrate that supra-
aortic angiography during preparatory BAV improves valve
size selection and reduces PAR and the associated mortality
after TAVI. Qualitatively, the frequency of post-procedural
PAR was lower in patients who underwent additional
balloon sizing than in those who underwent only conven-
tional sizing. Quantitative assessment of PAR severity by use
of the AR index, the pressure gradient DPDAP–LVEDP, and
the myocardial supply/demand ratio showed that the
frequency of exceeding the cutoff values that have previously
been associated with increased mortality was decreased in
the balloon-sizing group (11,14,15). Reduction of PAR and
its associated hemodynamic burden could play an importantTable 3. Assessment of PAR Severity
A
Conventional Sizing
(n ¼ 167)
Balloon Sizing
(n ¼ 103) p Value
Absent (0/4) 54 pts (32.3%) 62 pts (60.2%) <0.001
Trace or mild (1/4) 89 pts (53.3%) 33 pts (32%) <0.001
Moderate (2/4) 21 pts (12.6%) 7 pts (6.8%) <0.001
Moderate-to-severe (3/4) 3 pts (1.8%) 1 pts (1.0%) <0.001
Severe (4/4) 0 pts (0%) 0 pts (0%) <0.001
The distribution of post-procedural PAR was associated with the sizing method (A). An AR index <2
conventional- than in the balloon- sizing group (B).role in the improvement of outcome after TAVI, although
this remains speculative.
Aortic annulus sizing in TAVI. Accurate annulus measure-
ments and the selection of the appropriate prosthesis size are
critical in order to avoid valve migration, severe PAR, or
annulus rupture (2). The aortic annulus can be measured by
echocardiography, MSCT, or angiography. Recommenda-
tions for valve size selection are currently based on annular
measurements by TEE. Recent studies, however, show an
underestimation of the annulus size by echocardiography so
that possibly undersized valves are implanted (2). Given the
structure of the aortic root and semilunar-shaped cusps, 2-
dimensional imaging possibly “cuts” the oval plane at many
angles, resulting in inaccurate measurements (12,21). MSCT
is increasingly used for annular sizing and provides additional
anatomical information regarding the coronary arteries, the
aortic valve area, and the distribution of aortic valve calciﬁca-
tions (2,22–25). Although recent data show a correlation
between echocardiographic andMSCT sizing, results between
these methods are not identical (2). The calculation of the
annular diameter from maximum/minimum cross-sectional
diameter but also cross-sectional area has been proposed for
more accurate sizing (26); however, radiation exposure and
contrast medium injection are important limitations (2). In
a recent analysis, computed tomography sizing recommenda-
tions resulted in mean annular oversizing of 13.9% (27).
Use of preparatory BAV for improved valve size selection. Due
to conﬂicting measurements obtained with multimodal
imaging, asymmetric calciﬁcations, or eccentric leaﬂets, there
can be uncertainties regarding the optimal valve size selection
for TAVI (2,21). When measurements of the aortic annulus
are ambiguous between 2 different available prosthesis sizes,
valve size selection based only on indirect annular sizing
(TEE, MSCT) is critical (21). Therefore, in patients with
borderline annulus, currently available prostheses might be
undersized, resulting in annulus-to-device discrepancy. In this
setting, there was a tendency toward a lower cover index in
the retrospective conventional sizing group but without
signiﬁcance, probably due to the small number of patients
with relevant PAR. In our hands, supra-aortic angiography
during BAV provides a simple, direct, and effective measure
to improve sizing with a reduction of PAR frequency andB
Conventional Sizing
(n ¼ 167)
Balloon Sizing
(n ¼ 103) p Value
AR index <25 45 (26.9%) 16 (15.5%) 0.02
DpDAP–LVEDP 18 mm Hg 44 (26.3%) 15 (14.5%) 0.02
DPTI:SPTI 0.7 20 (11.9%) 5 (4.8%) 0.05
5, a Dp DAP–LVEDP 18 mm Hg and a DPTI:SPTI 0.7 were observed more frequently in the
Figure 3. Cumulative Survival According to the Sizing Method
Mortality at 30 days and 1 year was decreased in patients who underwent
additional balloon sizing in comparison to those who underwent only
conventional sizing (log-rank ¼ 0.03).
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970severity and therefore may serve in decision making on valve
size selection, especially in cases with borderline annulus size.
TAVI generally requires preparatory BAV to facilitate the
prosthesis implantation, and therefore balloon sizing cannot
be considered as an additional risk factor for stroke. On the
other hand, a reduced stroke rate was not observed due to
decreased rate of post-dilation in the balloon-sizing group.
In a recent study for the detection of procedural cerebral
microembolization during TAVI, the majority of high-
intensity transient signals (HITS) recorded by transcranial
Doppler ultrasonography was seen during direct valve
manipulation while positioning and implanting the pros-
thesis, revealing that the calciﬁed aortic valve is the main
source of emboli (28). In addition, the number of HITS
during BAV was unexpectedly low, possibly due to the
endothelial coverage preventing calciﬁc debris from release
and embolization at this stage of the procedure (28).
Although this explanation remains speculative, it is sup-
ported by the relatively low stroke rates of 1% to 2% reported
in a recent series of BAV (29).
Study limitations. Our data are derived from a retrospective
analysis of consecutive patients and not from a prospective,
randomized trial. We, therefore, cannot exclude that part of
the observed beneﬁt in group 2 versus group 1 is due to
a learning curve and not speciﬁcally to the technique of
balloon sizing. In addition, growing awareness of the clinical
impact of relevant PAR and therefore focus on avoidance of
annulus-to-prosthesis mismatch as well as better selection of
TAVI patients could have also played a role in the observed
beneﬁt in group 2 and are consequently potential con-
founders of our current study. The characteristics of theself-expandable nitinol frame of the MCV permit the selec-
tion of the larger valve to avoid PAR in cases of borderline
annulus size, but still complications such as atrioventricular
block may result (30). Taking the signiﬁcant discrepancies
(31) between measurements using 2- and 3-dimensional
imaging, but also the lack of sizing recommendations
based on 3-dimensional imaging under consideration, we
focused on the current manufacturer’s guidelines and used
2-dimensional TEE for annulus measurements. It remains
hypothetical whether we would have potentially used the
bigger valve in borderline cases without our current procedure
of valve sizing, but it must be noted that in 10 of 40 patients
with borderline annulus size, the smaller valve was ultimately
chosen.
Conclusions
At least mild PAR and quantitative parameters of PAR
severity, such as an AR index <25, a DPDAP–LVEDP 18
mm Hg, and a DPTI:SPTI 0.7, all associated with an
increased mortality, were observed less often in patients
who underwent additional balloon sizing than in those
who underwent only conventional sizing. Preparatory
BAV during TAVI improves valve size selection, reduces
PAR, and thus improves survival, especially in borderline
cases.
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